Optimizing the FNR in patients receiving NACT for a biopsy-proven node-positive breast is important because understaging the residual axillary disease can potentially result in adjuvant systemic therapy undertreatment and compromise of oncological outcome in patients particularly with HER2-positive and triple-negative breast cancer (TNBC) where residual disease is used to guide the use of further adjuvant systemic therapy, such as capecitabine for TNBC and TD-M1 for HER2-positive disease [2]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.